Life sciences IP practitioners warn that AI-driven innovation is outpacing existing patent frameworks as questions over inventorship and ownership of AI-generated discoveries remain unresolved
A Law360 analysis in the life sciences sector highlights the growing tension between AI-driven innovation in drug discovery and diagnostics and the intellectual property frameworks designed to protect it. As AI tools generate outputs — molecular structures, diagnostic algorithms, novel compound candidates — that may qualify as patentable inventions, fundamental questions remain unresolved: who is the inventor where an AI system contributed materially to a discovery, and how should ownership be allocated between the AI developer, the life sciences company deploying the tool, and the human researchers directing its use? These questions have direct commercial stakes. Patent protection is the primary mechanism by which life sciences companies defend the commercial value of their R&D investment. If AI-generated innovations cannot be effectively patented — or if ownership disputes arise between the AI vendor and the drug developer — the economics of AI-assisted drug discovery are materially affected. The UKIPO has been among the patent offices engaging with these questions, and the UK Courts have previously considered (in non-life-sciences contexts) whether AI-generated outputs can qualify for patent protection. The unresolved status of AI inventorship in UK, EU, and US patent law creates a three-jurisdiction advisory problem for global life sciences companies that develop AI tools across multiple regulatory regimes simultaneously. For law firm AI and IP practices, the emerging demand is for bespoke IP ownership structuring in AI-assisted R&D agreements, alongside proactive patent prosecution strategies that pre-emptively address inventorship questions before the first patent application is filed.
Why this matters
AI-driven innovation in life sciences creates a category of IP that existing patent law was not designed to handle: inventions where the creative or inventive contribution is distributed across a human team, an AI system, and the dataset on which that system was trained. For UK-qualified lawyers advising global life sciences clients, this creates demand for choice-of-law analysis (which jurisdiction's patent regime is most favourable for AI-assisted inventions?), technology licensing review (does the AI vendor's licence give the life sciences company sufficient rights to claim patent ownership over outputs?), and IP due diligence in M&A transactions (is the target's AI-generated patent portfolio actually defensible?). The 'why now' driver is the accelerating deployment of AI in drug discovery — from target identification through clinical trial design — which means these questions are moving from theoretical to transactional at pace.
On the Ground
On an AI-assisted life sciences IP mandate, a trainee would assist with technology licence review — specifically checking whether the licence agreement grants sufficient IP ownership rights over AI-generated outputs — and data processing agreement markup where training data use is in question. They would also assist with AI governance policy drafting and vendor due diligence questionnaires where the client is assessing a new AI tool for R&D use.
Interview prep
Question you might get
“A life sciences company has used an AI platform, licensed from a third-party vendor, to identify a novel drug target. The vendor's licence is silent on IP ownership of AI-generated outputs. How would you advise the client on its patent strategy, and what contractual remedies should it seek retroactively?”
Sign up free to see the full answer
A model answer you can lift into an interview — how to frame this story for a partner.
Sign up freeMy notes
saved